Non-Hodgkin's lymphoma in the microarray era

Clinical Lymphoma

Volumn 5, Issue 2, 2004, Pages 128-129

  Lossos, Izidore S ^a,b   Morgensztern, Daniel ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MYC PROTEIN;

B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DIAGNOSTIC VALUE; DNA MICROARRAY; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; NOTE; PATHOPHYSIOLOGY; PREDICTION; PROGNOSIS; STATISTICAL MODEL;

EID: 5744220633     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9655(11)70069-0     Document Type: Note

References (25)

1. Jemal A, Tiwari RC, Murray, T, et al. Cancer statistics, 2004. CA Cancer J Clin 2003; 54:8-29.
2. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-1392.
3. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
4. Dybkaer K, Iqbal J, Zhou G, et al. Molecular diagnosis and outcome prediction in diffuse large B-cell lymphoma and other subtypes of lymphoma. Clin Lymph 2004; 5:19-28.
5. Alizadeh AA, Elsen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511.
6. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 2002; 346:1937-1947.
7. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74.
8. Rosenwald A, Wright G, Wiestner A, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003; 3:185-197.
9. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappa B activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194:1861-1874.
10. Lossos IS, Alizadeh AA, Diehn M, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A 2002; 99:8886-8891.
11. Elenitoba-Johnson KS, Jenson SD, Abbott RT et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A 2003; 100:7259-7564.
12. Lossos IS, Alizadeh AA, Rajapaska R, et al. HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood 2003; 101:433-440.
13. Bohen SP, Troyanskaya OG, Alter O, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A 2003; 100:1926-1930.
14. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194:1625-1638.
15. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194:1639-1647.
16. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851-862.
17. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. Blood 2003; 102:3871-3879.
18. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95:14863-14868.
19. Tamayo P, Slonim D, Mesirov J, et al. Interpreting patterns of gene expression with self-organizing maps: Methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 1999; 96:2907-2912.
20. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003; 100:9991-9996.
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98:5116-5121.
22. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103:275-282.
23. Barrans SL, Carter I, Owen RG, et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99:1136-1143.
24. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101:78-84.
25. Lossos IS, Jones KD, Warnke R, et al. The expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 2001; 98:945-951.